NGM’s Pan-FGF Receptor Approach In NASH Shows Benefits And Drawbacks
Executive Summary
NGM’s Phase II data for FGF19 analog aldafermin shows ability to reduce liver fat and improve fibrosis, but also raises LDL-C. Company says it gets a broader effect this way and can manage the increased cholesterol.